Skip to Content

Biomed-Lublin Wytwornia Surowic i Szczepionek SA - Stock Quote BML

Rating as of

Morningstar's Biomed-Lublin Wytwornia Surowic i Szczepionek SA Stock Analysis

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Biomed-Lublin Wytwornia Surowic i Szczepionek SA's Company Profile

Business Description

Biomed-Lublin Wytwornia Surowic i Szczepionek SA is a pharmaceutical company. The company is engaged in the developing products and therapeutic indications and conducting clinical trials in cooperation with scientific and medical centers. Its products include Prescription drugs, Medical products and Report an adverse reaction.

Contact
ulica University 10
Lublin, 20-029, Poland
T +48 815338221
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2019
Stock Type
Employees 223